Last reviewed · How we verify
Gliclazide Group
At a glance
| Generic name | Gliclazide Group |
|---|---|
| Also known as | metformin |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Hypoglycaemia
- Constipation
- Bronchitis
- Back pain
- Gastroenteritis
- Influenza
- Headache
- Arthralgia
Key clinical trials
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- HbA1c Variability in Type II Diabetes (NA)
- Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial (NA)
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients (PHASE3)
- Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
- Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity (PHASE4)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: